This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Metabasis, Valeant Rise

Shares of drug developers Valeant Pharmaceuticals (VRX - Get Report) and Metabasis Therapeutics (MBRX) jumped in after-hours trading Wednesday after the companies announced licensing agreements with drug giant Schering-Plough (SGP) for a new hepatitis B treatment.

Schering-Plough has licensed exclusive worldwide rights to develop and market the investigational treatment, pradefovir, for patients with chronic hepatitis B. Valeant initially licensed pradefovir from Metabasis in 2000 and has been evaluating the drug's safety and efficacy in treating the disease. The drug uses Metabasis' so-called HepDirect technology to direct higher drug concentrations into the liver, the primary site where the hepatitis B virus replicates.

"Pradefovir has the potential to offer improved treatment options for patients with chronic hepatitis B, a serious blood-borne infection affecting some 400 million people worldwide," said Dr. Robert Spiegel, chief medical officer of Schering-Plough Research Institute.

The transaction is expected to close in the first quarter of 2007, pending customary closing conditions. Under the terms of the deal, Schering-Plough will make upfront payments to Valeant and Metabasis and will pay additional fees to the companies upon the achievement of certain development and regulatory milestones.

Schering-Plough will fund all future research and development activities including clinical studies and regulatory filings, and will pay both of the companies royalties if the drug enters the market.

Valeant's shares gained 3.7% to $17.52 and Metabasis jumped 6.3% to $8.30 in after-hours trading, while Schering-Plough's shares were down 6 cents to $23.24.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
VRX $202.02 0.00%
AAPL $134.95 1.70%
FB $81.91 0.00%
GOOG $555.37 0.00%
TSLA $232.72 0.51%


DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs